Trial Profile
Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Cardiac Surgery
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tezosentan (Primary)
- Indications Cardiovascular disorders; Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms TACTICS
- Sponsors Actelion Pharmaceuticals
- 27 Nov 2015 New source identified and integrated (NCT00458276).
- 27 Nov 2015 New trial record